AstraZeneca data at WCLC advance ambition to have an AstraZeneca medicine for more than half of all patients treated for lung cancer by 2030
FLAURA2 data reinforce Tagrisso as backbone therapy for EGFR-mutated advanced lung cancer in combination with chemotherapy; granted Breakthrough Therapy Designation in the US. Further results for Enhertu, Imfinzi and datopotamab deruxtecan showcase strength of diverse ADC and IO portfolios to address unmet needs. AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), 9 to 12 September 2023. More than 40 abstracts will feature eight approved and potential new